Yon Ho Choe

3 weeks ago | nature.com | Seon Young Kim |Yiyoung Kwon |Eun Sil Kim |Yoon Kim |Hansol Kim |Yon Ho Choe

AbstractA pilot study investigated the cytokine profile (IL-6, TNF-α, IL-17 A, and IL-10) at diagnosis, affecting infliximab (IFX) trough levels (TLs) in pediatric patients with Crohn’s disease (CD). In this follow-up study, we evaluated the changes in cytokine level changes after Crohn’s disease treatment. Cytokines were re-measured after 1 year of treatment. infliximab trough levels and total anti-infliximab antibodies were also measured in patients who had started infliximab treatment.